ES2270638T3 - Deteccion de microorganismos acido-resistentes en las heces. - Google Patents
Deteccion de microorganismos acido-resistentes en las heces. Download PDFInfo
- Publication number
- ES2270638T3 ES2270638T3 ES99971515T ES99971515T ES2270638T3 ES 2270638 T3 ES2270638 T3 ES 2270638T3 ES 99971515 T ES99971515 T ES 99971515T ES 99971515 T ES99971515 T ES 99971515T ES 2270638 T3 ES2270638 T3 ES 2270638T3
- Authority
- ES
- Spain
- Prior art keywords
- antibody
- antigen
- fragment
- epitope
- cdr3
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 244000005700 microbiome Species 0.000 title claims abstract description 43
- 238000001514 detection method Methods 0.000 title claims description 70
- 239000012634 fragment Substances 0.000 claims abstract description 151
- 239000000427 antigen Substances 0.000 claims abstract description 110
- 108091007433 antigens Proteins 0.000 claims abstract description 108
- 102000036639 antigens Human genes 0.000 claims abstract description 108
- 108091023037 Aptamer Proteins 0.000 claims abstract description 106
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 61
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 61
- 241000124008 Mammalia Species 0.000 claims abstract description 60
- 239000002253 acid Substances 0.000 claims abstract description 38
- 208000015181 infectious disease Diseases 0.000 claims abstract description 28
- 239000006166 lysate Substances 0.000 claims abstract description 22
- 210000004408 hybridoma Anatomy 0.000 claims abstract description 21
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 20
- 239000000203 mixture Substances 0.000 claims abstract description 20
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 20
- 238000012360 testing method Methods 0.000 claims abstract description 18
- 239000000284 extract Substances 0.000 claims abstract description 17
- 238000000034 method Methods 0.000 claims description 107
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims description 82
- 108010046334 Urease Proteins 0.000 claims description 39
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 37
- 238000002965 ELISA Methods 0.000 claims description 31
- 230000000968 intestinal effect Effects 0.000 claims description 24
- 101710154868 60 kDa heat shock protein, mitochondrial Proteins 0.000 claims description 22
- 102100038222 60 kDa heat shock protein, mitochondrial Human genes 0.000 claims description 22
- 102000007456 Peroxiredoxin Human genes 0.000 claims description 21
- 108030002458 peroxiredoxin Proteins 0.000 claims description 21
- 241000894006 Bacteria Species 0.000 claims description 20
- 230000003053 immunization Effects 0.000 claims description 20
- 238000002649 immunization Methods 0.000 claims description 20
- 108010058432 Chaperonin 60 Proteins 0.000 claims description 17
- 102000006303 Chaperonin 60 Human genes 0.000 claims description 17
- 101000609456 Beet necrotic yellow vein virus (isolate Japan/S) Protein P26 Proteins 0.000 claims description 16
- 210000003608 fece Anatomy 0.000 claims description 16
- 239000000463 material Substances 0.000 claims description 15
- 238000004458 analytical method Methods 0.000 claims description 12
- 230000027455 binding Effects 0.000 claims description 12
- 108020004414 DNA Proteins 0.000 claims description 11
- 241000590002 Helicobacter pylori Species 0.000 claims description 11
- 150000001413 amino acids Chemical class 0.000 claims description 11
- 239000000872 buffer Substances 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 9
- 102000002812 Heat-Shock Proteins Human genes 0.000 claims description 7
- 108010004889 Heat-Shock Proteins Proteins 0.000 claims description 7
- 101710087887 Alkyl hydroperoxide reductase C Proteins 0.000 claims description 6
- 241000187479 Mycobacterium tuberculosis Species 0.000 claims description 6
- 210000000440 neutrophil Anatomy 0.000 claims description 6
- 239000002245 particle Substances 0.000 claims description 6
- 241000589875 Campylobacter jejuni Species 0.000 claims description 5
- 241000589989 Helicobacter Species 0.000 claims description 5
- 206010019375 Helicobacter infections Diseases 0.000 claims description 5
- 101001086866 Sus scrofa Pulmonary surfactant-associated protein B Proteins 0.000 claims description 5
- 239000001913 cellulose Substances 0.000 claims description 5
- 229920002678 cellulose Polymers 0.000 claims description 5
- 230000009918 complex formation Effects 0.000 claims description 5
- 229940037467 helicobacter pylori Drugs 0.000 claims description 5
- 239000007790 solid phase Substances 0.000 claims description 5
- 241000186359 Mycobacterium Species 0.000 claims description 4
- 230000003213 activating effect Effects 0.000 claims description 4
- 238000004040 coloring Methods 0.000 claims description 4
- 230000001900 immune effect Effects 0.000 claims description 4
- 238000011534 incubation Methods 0.000 claims description 4
- 101710112984 20 kDa protein Proteins 0.000 claims description 3
- 102000001390 Fructose-Bisphosphate Aldolase Human genes 0.000 claims description 3
- 108010068561 Fructose-Bisphosphate Aldolase Proteins 0.000 claims description 3
- 241001453258 Helicobacter hepaticus Species 0.000 claims description 3
- 101710159910 Movement protein Proteins 0.000 claims description 3
- 101710090398 Viral interleukin-10 homolog Proteins 0.000 claims description 3
- 241000589876 Campylobacter Species 0.000 claims description 2
- 102100029812 Protein S100-A12 Human genes 0.000 claims description 2
- 101710110949 Protein S100-A12 Proteins 0.000 claims description 2
- YRKCREAYFQTBPV-UHFFFAOYSA-N acetylacetone Chemical compound CC(=O)CC(C)=O YRKCREAYFQTBPV-UHFFFAOYSA-N 0.000 claims description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 2
- 239000004816 latex Substances 0.000 claims description 2
- 229920000126 latex Polymers 0.000 claims description 2
- 238000003127 radioimmunoassay Methods 0.000 claims description 2
- 238000001262 western blot Methods 0.000 claims description 2
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 claims 28
- 108091000080 Phosphotransferase Proteins 0.000 claims 1
- 102000020233 phosphotransferase Human genes 0.000 claims 1
- 241001465754 Metazoa Species 0.000 abstract description 8
- 210000000936 intestine Anatomy 0.000 abstract description 7
- 230000000694 effects Effects 0.000 abstract description 3
- 238000012545 processing Methods 0.000 abstract description 3
- 230000002550 fecal effect Effects 0.000 abstract 3
- 108010047041 Complementarity Determining Regions Proteins 0.000 abstract 2
- 230000000844 anti-bacterial effect Effects 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 230000010534 mechanism of action Effects 0.000 abstract 1
- 244000052769 pathogen Species 0.000 description 22
- 239000000523 sample Substances 0.000 description 17
- 244000045947 parasite Species 0.000 description 12
- 239000000126 substance Substances 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 9
- 239000012228 culture supernatant Substances 0.000 description 9
- 238000003745 diagnosis Methods 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- 239000012528 membrane Substances 0.000 description 9
- 230000001717 pathogenic effect Effects 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 8
- 102000003992 Peroxidases Human genes 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 108040007629 peroxidase activity proteins Proteins 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- 230000001580 bacterial effect Effects 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 101150038787 mak gene Proteins 0.000 description 6
- 239000008188 pellet Substances 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 235000020183 skimmed milk Nutrition 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 238000012408 PCR amplification Methods 0.000 description 5
- 229920001213 Polysorbate 20 Polymers 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 238000012512 characterization method Methods 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 238000002405 diagnostic procedure Methods 0.000 description 5
- 238000003119 immunoblot Methods 0.000 description 5
- 239000011159 matrix material Substances 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 5
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 239000011534 wash buffer Substances 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 210000001124 body fluid Anatomy 0.000 description 4
- 239000010839 body fluid Substances 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 238000005520 cutting process Methods 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 235000002639 sodium chloride Nutrition 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 241000701161 unidentified adenovirus Species 0.000 description 4
- 210000002700 urine Anatomy 0.000 description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000007995 HEPES buffer Substances 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 206010036790 Productive cough Diseases 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 230000008033 biological extinction Effects 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 230000029142 excretion Effects 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 238000013507 mapping Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- 210000003802 sputum Anatomy 0.000 description 3
- 208000024794 sputum Diseases 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 238000012286 ELISA Assay Methods 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 108090001090 Lectins Proteins 0.000 description 2
- 102000004856 Lectins Human genes 0.000 description 2
- 241000589248 Legionella Species 0.000 description 2
- 208000007764 Legionnaires' Disease Diseases 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 239000012506 Sephacryl® Substances 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 108091006088 activator proteins Proteins 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000037029 cross reaction Effects 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000003795 desorption Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000002523 lectin Substances 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 238000002823 phage display Methods 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 230000003595 spectral effect Effects 0.000 description 2
- 238000004611 spectroscopical analysis Methods 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- -1 26 kda Proteins 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- HSTOKWSFWGCZMH-UHFFFAOYSA-N 3,3'-diaminobenzidine Chemical compound C1=C(N)C(N)=CC=C1C1=CC=C(N)C(N)=C1 HSTOKWSFWGCZMH-UHFFFAOYSA-N 0.000 description 1
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- 108010032595 Antibody Binding Sites Proteins 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 238000012492 Biacore method Methods 0.000 description 1
- 108010039206 Biotinidase Proteins 0.000 description 1
- 102100026044 Biotinidase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 241001647372 Chlamydia pneumoniae Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 241000224431 Entamoeba Species 0.000 description 1
- 241000224432 Entamoeba histolytica Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108010008177 Fd immunoglobulins Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241001473949 Helicobacter pylori NCTC 11637 = CCUG 17874 = ATCC 43504 Species 0.000 description 1
- 208000028861 Helicobacter pylori infectious disease Diseases 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 241000282341 Mustela putorius furo Species 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 241000282376 Panthera tigris Species 0.000 description 1
- 241000479842 Pella Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 241000233872 Pneumocystis carinii Species 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 241000244159 Taenia saginata Species 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- 208000025087 Yersinia pseudotuberculosis infectious disease Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000011091 antibody purification Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- SYLKGLMBLAAGSC-QLVMHMETSA-N cefsulodin Chemical compound C1=CC(C(=O)N)=CC=[N+]1CC1=C(C([O-])=O)N2C(=O)[C@@H](NC(=O)[C@@H](C=3C=CC=CC=3)S(O)(=O)=O)[C@H]2SC1 SYLKGLMBLAAGSC-QLVMHMETSA-N 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000002925 chemical effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000012631 diagnostic technique Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 229940007078 entamoeba histolytica Drugs 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 210000004201 immune sera Anatomy 0.000 description 1
- 229940042743 immune sera Drugs 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 238000013492 plasmid preparation Methods 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229940057838 polyethylene glycol 4000 Drugs 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 238000000734 protein sequencing Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- 229940118696 vibrio cholerae Drugs 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
- G01N33/56922—Campylobacter
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/121—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Helicobacter (Campylobacter) (G)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
- G01N2333/205—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Campylobacter (G)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- Virology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP98120517 | 1998-10-29 | ||
| EP98120517 | 1998-10-29 | ||
| EP98120687 | 1998-11-06 | ||
| EP98120687 | 1998-11-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2270638T3 true ES2270638T3 (es) | 2007-04-01 |
Family
ID=26149749
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES99971515T Expired - Lifetime ES2270638T3 (es) | 1998-10-29 | 1999-10-29 | Deteccion de microorganismos acido-resistentes en las heces. |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US7122320B2 (enExample) |
| EP (2) | EP1734366A3 (enExample) |
| JP (1) | JP2002529705A (enExample) |
| AT (1) | ATE334395T1 (enExample) |
| AU (1) | AU1157100A (enExample) |
| DE (1) | DE59913716D1 (enExample) |
| DK (1) | DK1125130T3 (enExample) |
| ES (1) | ES2270638T3 (enExample) |
| WO (1) | WO2000026671A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1734366A3 (de) * | 1998-10-29 | 2007-11-07 | Oxoid (Ely) Limited | Neues Verfahren zum Nachweis von Säure-resistenten Mikroorganismen im Stuhl |
| EP1232392B2 (de) * | 1999-10-12 | 2014-04-02 | Oxoid (Ely) Limited | Verbessertes verfahren zum nachweis von säure-resistenten bakterien der gattung helicobacter im stuhl |
| JP3504633B2 (ja) | 1999-10-29 | 2004-03-08 | わかもと製薬株式会社 | ヘリコバクター・ピロリへの感染を判定する検査方法及び検査試薬 |
| EP1227159B1 (en) | 1999-10-29 | 2011-04-20 | Wakamoto Pharmaceutical Co., Ltd. | Monoclonal antibody, hybridoma, immunoassay method and diagnosis kit |
| DE60138981D1 (de) * | 2000-05-18 | 2009-07-30 | Meridian Bioscience Inc | Immunoassay für H. pylori in Fäkalienproben mit Hilfe von gattungsspezifischen Antikörpern |
| DE10043161A1 (de) * | 2000-09-01 | 2002-03-14 | Connex Ges Zur Optimierung Von | Lösung zur Aufbereitung von Stuhlproben für diagnostische Zwecke |
| BR0207068A (pt) * | 2001-01-26 | 2004-12-21 | Inhibitex Inc | Anticorpo monoclonal para a protéina clfa, anti-soro isolado, anticorpo isolado e anticorpo humanizado contendo o referido anticorpo, kit diagnóstico compreendendo o referido anticorpo, método para diagnóstico de uma infecção por s.aureus, composição farmacêutica para o tratamento ou prevenção da referida infecção, método para indução de de uma resposta imunológica, método para identificação de anticorpos monoclonais para a protéina clfa e fragmento ativo isolado a partir do domìnio a da protéina clfa do s.aureus |
| FI118061B (fi) | 2001-09-24 | 2007-06-15 | Beanor Oy | Menetelmä ja bioanturi analyysiä varten |
| FI115166B (fi) | 2001-12-31 | 2005-03-15 | Biofons Oy | Diagnostisia menetelmiä |
| US20040023415A1 (en) * | 2002-03-05 | 2004-02-05 | Konstantin Sokolov | Biospecific contrast agents |
| DE10219741A1 (de) * | 2002-05-02 | 2003-11-13 | Georg S Wengler | Verfahren zur Vorbehandlung von Stuhlproben |
| GB0210783D0 (en) * | 2002-05-10 | 2002-06-19 | Polonelli Luciano | Anti-microbial polypeptides |
| US20090191213A9 (en) | 2003-07-02 | 2009-07-30 | Novo Nordisk A/S | Compositions and methods for regulating NK cell activity |
| KR20060079180A (ko) * | 2003-07-02 | 2006-07-05 | 노보 노르디스크 에이/에스 | Ｎｋ 세포 활성을 조절하기 위한 조성물 및 방법 |
| DK2287195T3 (da) * | 2004-07-01 | 2019-08-19 | Innate Pharma | Pan-kir2dl nk-receptor-antistoffer og anvendelse heraf i diagnostik og terapi |
| DE602005026538D1 (de) * | 2004-07-01 | 2011-04-07 | Innate Pharma | An die rezeptoren kir2dl1, -2, -3, jedoch nicht kir2ds4, bindende antikörper und deren therapeutische verwendung |
| JP4625318B2 (ja) * | 2004-12-06 | 2011-02-02 | 財団法人野田産業科学研究所 | 相同組換え頻度が上昇した形質転換菌 |
| PL1836225T3 (pl) | 2005-01-06 | 2012-05-31 | Novo Nordisk As | Czynniki wiążące kir i sposoby ich stosowania |
| WO2009088460A2 (en) * | 2008-01-03 | 2009-07-16 | Ask Diagnostics, Inc. | Methods of diagnosing latent and active malignancies |
| US20110065086A1 (en) * | 2008-02-21 | 2011-03-17 | Otc Biotechnologies, Llc | Methods of producing homogeneous plastic-adherent aptamer-magnetic bead-fluorophore and other sandwich assays |
| CA2871081A1 (en) * | 2011-04-21 | 2012-10-26 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Peptide and conjugate vaccines for fungal infections |
| WO2016176176A1 (en) * | 2015-04-29 | 2016-11-03 | 3M Innovative Properties Company | Culture device for anaerobic microorganisms |
| CN109628457B (zh) * | 2019-02-03 | 2021-12-10 | 淮海工学院 | 单链dna核酸适配体及其筛选方法与用途 |
| CN110618270B (zh) * | 2019-09-10 | 2020-08-25 | 深圳市鸿美诊断技术有限公司 | 一种用于定量测定粪便中幽门螺杆菌抗原试剂的制备方法 |
| EP4204003A4 (en) * | 2020-08-28 | 2024-08-21 | Board of Regents, The University of Texas System | ANTIBODIES SPECIFIC TO CCL21 AND METHODS OF USE |
| TW202317188A (zh) * | 2021-06-22 | 2023-05-01 | 美商通用醫院公司 | 於癌症中治療靶向鈣黏蛋白11 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4879213A (en) * | 1986-12-05 | 1989-11-07 | Scripps Clinic And Research Foundation | Synthetic polypeptides and antibodies related to Epstein-Barr virus early antigen-diffuse |
| JPS63273497A (ja) * | 1986-12-26 | 1988-11-10 | Meiji Seika Kaisha Ltd | 抗カンピロバクターモノクローナル抗体 |
| US5200344A (en) * | 1990-11-13 | 1993-04-06 | Blaser Martin J | Diagnostic testing for campylobacter jejuni or campylobacter coli infections using novel antigens |
| WO1996034624A1 (en) * | 1995-05-02 | 1996-11-07 | Institut Pasteur | Immunogenic compositions against helicobacter infection, polypeptides for use in the compositions, and nucleic acid sequences encoding said polypeptides |
| GB2307987A (en) * | 1995-12-06 | 1997-06-11 | Univ Manchester | Epitopes of the urease of Helicobacter pylori as dignostic agents; pharmaceuticals comprising such epitopes or the antibodies thereto |
| US5716791A (en) * | 1996-05-09 | 1998-02-10 | Meridian Diagnostics, Inc. | Immunoassay for H. pylori in fecal specimens |
| US5932430A (en) * | 1996-05-09 | 1999-08-03 | Meridian Diagnostics, Inc. | Immunoassay for H. pylori in fecal specimens |
| US6383763B1 (en) * | 1996-07-26 | 2002-05-07 | Case Western Reserve University | Detection of mycobacteria |
| IT1289578B1 (it) * | 1996-12-06 | 1998-10-15 | Sanitaria Scaligera Spa | Immunopurificazione di un antigene dall'apparente peso molecolare di 16 +- 2 kda dell' helicobacter pylori e metodi per la sua |
| EP1734366A3 (de) * | 1998-10-29 | 2007-11-07 | Oxoid (Ely) Limited | Neues Verfahren zum Nachweis von Säure-resistenten Mikroorganismen im Stuhl |
-
1999
- 1999-10-29 EP EP06015257A patent/EP1734366A3/de not_active Withdrawn
- 1999-10-29 AU AU11571/00A patent/AU1157100A/en not_active Abandoned
- 1999-10-29 AT AT99971515T patent/ATE334395T1/de not_active IP Right Cessation
- 1999-10-29 DK DK99971515T patent/DK1125130T3/da active
- 1999-10-29 JP JP2000580001A patent/JP2002529705A/ja not_active Ceased
- 1999-10-29 DE DE59913716T patent/DE59913716D1/de not_active Expired - Lifetime
- 1999-10-29 EP EP99971515A patent/EP1125130B1/de not_active Expired - Lifetime
- 1999-10-29 WO PCT/EP1999/008212 patent/WO2000026671A1/de not_active Ceased
- 1999-10-29 ES ES99971515T patent/ES2270638T3/es not_active Expired - Lifetime
-
2001
- 2001-04-27 US US09/842,776 patent/US7122320B2/en not_active Expired - Lifetime
-
2006
- 2006-08-31 US US11/513,129 patent/US7736859B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US7736859B2 (en) | 2010-06-15 |
| JP2002529705A (ja) | 2002-09-10 |
| AU1157100A (en) | 2000-05-22 |
| US7122320B2 (en) | 2006-10-17 |
| DK1125130T3 (da) | 2006-11-27 |
| EP1125130B1 (de) | 2006-07-26 |
| DE59913716D1 (de) | 2006-09-07 |
| WO2000026671A1 (de) | 2000-05-11 |
| US20040023316A1 (en) | 2004-02-05 |
| EP1734366A2 (de) | 2006-12-20 |
| EP1734366A3 (de) | 2007-11-07 |
| US20070009975A1 (en) | 2007-01-11 |
| ATE334395T1 (de) | 2006-08-15 |
| EP1125130A1 (de) | 2001-08-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2270638T3 (es) | Deteccion de microorganismos acido-resistentes en las heces. | |
| US7129053B1 (en) | Immuno-chromatographic rapid assay in order to detect acid-resistant microorganisms in the stool | |
| KR0165691B1 (ko) | 장출혈성 대장균 015:h7 및 026:h11에 대한 단일클론 항체 및 검출 방법 | |
| CN106706914B (zh) | 用于诊断上皮源性癌症的血液标志物及单克隆抗体 | |
| US10227395B2 (en) | Monoclonal antibodies that neutralize anthrax protective antigen (PA) toxin | |
| CA2714720A1 (en) | Antibodies to clostridium difficile spores and uses thereof | |
| US8906635B2 (en) | Methods of diagnosing Clostridium difficile infection | |
| US5294537A (en) | Monoclonal antibody assay for Listeria monocytogenes | |
| CN116693681B (zh) | 抗幽门螺杆菌细胞毒素相关蛋白a的单克隆抗体及其应用 | |
| US20120282274A1 (en) | Targeting of the c-terminal segment of c.difficile toxin b for improved clinical diagnosis, prevention, and treatment | |
| CN117700560B (zh) | 抗艰难梭菌谷氨酸脱氢酶的单克隆抗体及其应用 | |
| US20250034237A1 (en) | Methods, Devices, Kits and Compositions for Detecting Tapeworm | |
| KR101263913B1 (ko) | 우결핵 진단 키트 및 이를 이용한 우결핵 진단 방법 | |
| Lee et al. | Characterization of chicken-derived antibody against Alpha-Enolase of Streptococcus pneumoniae | |
| BR112019014299A2 (pt) | Método para diagnosticar ou monitorar infecção, anticorpos, usos, fragmento de peptídeo e método para gerar um anticorpo que se liga especificamente a map p900 | |
| EP0915158A2 (en) | Improvements in or relating to detection of salmonella | |
| Kim | Development of the rapid immunoassay methods for the screening of Listerial contamination | |
| CA2248171A1 (en) | Improvements in or relating to detection of salmonella |